Drug Profile
Research programme: SeV-based gene therapies - ID Pharma/Sumitomo Pharma
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator DNAVEC Corporation
- Developer ID Pharma; Sumitomo Pharma
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Eye disorders
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Oct 2018 No recent reports of development identified for research development in CNS-disorders in Japan (Parenteral)
- 28 Oct 2018 No recent reports of development identified for research development in Eye-disorders in Japan (Ophthalmic)